GWM
TEVA icon

Graybill Wealth Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Graybill Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-303
Closed -$4.66K – 167
2025
Q1 		$4.66K Buy
+303
New +$5.41K ﹤0.01% 169

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Graybill Wealth Management's TEVA Position: Q2 2025 in Review

Graybill Wealth Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q2 2025, closing a stake of 303 shares — an estimated $4.66K sold.

Graybill Wealth Management first reported a position in TEVA in Q1 2025 and held it in 1 quarter. The position peaked at $4.66K in Q1 2025. 541 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • Graybill Wealth Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q2 2025 after selling out during the quarter.
  • Graybill Wealth Management sold 303 Teva Pharmaceutical Industries Limited shares in Q2 2025, an estimated $4.66K.
  • Graybill Wealth Management first reported a position in Teva Pharmaceutical Industries Limited in Q1 2025 and held it in 1 quarter.
  • Graybill Wealth Management's Teva Pharmaceutical Industries Limited position peaked at $4.66K in Q1 2025.
  • 541 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2025.

Based on Graybill Wealth Management's 13F filing for Q2 2025, filed 31 Jul 2025.